Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cognitive function after liver transplantation comparing tacrolimus formulations
2018-004043-23Phase 4Active
- Sponsor
- University Hospital Schleswig-Holstein
- Start
- Apr 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of tacrolimus in immunocompromise (2 arms), sponsored by University Hospital Schleswig-Holstein. Primary endpoint: Change in subjective attention/concentration and memory (FEDA) at 6 months. Started Apr 2020; status: active.
02
Drugs
tacrolimus
03
Conditions
immunocompromise
Beyond the preview
Go deeper on 2018-004043-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004043-23.